Compare Amylx Pharmaceuticals Inc (AMLX) vs Chewy Inc (CHWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Chewy Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $22.57 (market cap $2.60B), while Chewy Inc trades at $22.46 (market cap $9.15B). The key difference: Chewy Inc is far larger — about 3.5× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Chewy Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | CHWY | |
|---|---|---|
Market Cap | $2.60B | $9.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $42.33 |
52-Week Low | $7.82 | $17.51 |
Enterprise Value | $2.36B | $9.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, down 1.18% on the day, with strong analyst support (90.9% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum with moving averages supporting upward movement, though RSI levels indicate potential overbought conditions. Recent Q2 2026 earnings missed expectations with a loss of $0.39 per share, but the company maintains significant cash reserves through 2028 and anticipates key Phase 3 trial results for avexitide in late August/September 2026.
The investment case hinges on successful clinical trial outcomes and future revenue generation, with current negative profitability metrics offset by strong institutional backing and promising pipeline catalysts. Key risks include clinical trial failures, ongoing financial losses, and competitive pressures in the biotech sector.
Chewy (CHWY) trades at $22.46, down 0.04% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $11.86B in 2025 and a net income of $392.74M, though Q2 2026 EPS is yet to be reported. Recent news highlights institutional buying and selling activity, with Zacks and The Motley Fool discussing its growth and value potential.
The outlook is mixed: analyst consensus is strongly bullish with an 81.58% buy rating and a $33.82 price target, implying significant upside. However, risks include competitive pressures, volatile earnings, and a high P/E ratio of 37.25. Cash flow trends show variability, with net cash flow negative in 2025, requiring careful monitoring of operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →
